2425 55th Street, Suite 210 Boulder, CO 80301 303-420-4420

Bolder BioTechnology to Present Preclinical Data for Three Research Programs at Acute Radiation Syndrome Meeting

Boulder, Colorado – October 24, 2018- Bolder BioTechnology, Inc. announced today that Dr. Joe Cox, Company President, will give an oral presentation at the “A Poly-Pharmacy Approach to Mitigate Acute Radiation Syndrome (ARS)” meeting being held October 25, 2018 at the National Institute of Allergy and Infectious Diseases Conference Center, 5601 Fishers Lane, Rockville, Maryland. The title of Dr. Cox’s presentation is “Improving survival in a mouse H-ARS model using combinations of hematopoietic growth factors and an ACE inhibitor.” The meeting is being sponsored by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.

Dr. Cox’s presentation will include results of animal studies using combinations of the company’s long-acting analogs of granulocyte-macrophage colony-stimulating factor (BBT-007), granulocyte- colony-stimulating factor (BBT-015), and interleukin-11 (BBT-059) to treat acute radiation syndrome. Each of these proteins has demonstrated the ability to increase survival and accelerate recovery of multiple blood cell types following exposure of animals to high doses of ionizing radiation.

About Acute Radiation Syndrome (ARS)
ARS is a collection of illnesses that occurs following exposure to high doses of ionizing radiation within a short period of time, such as might occur following an accident at a nuclear power plant or detonation of a nuclear weapon. Bone marrow, which is where most new blood cells are formed, is one of the most radiation-sensitive tissues, and subjects acutely exposed to high doses of radiation typically develop bone marrow aplasia and severe neutropenia (low numbers of neutrophils) and thrombocytopenia (low numbers of platelets) within days to weeks of exposure (referred to as the hematopoietic acute radiation syndrome or H-ARS). Many subjects die during this time period from infections (due to a lack of neutrophils) or from uncontrolled bleeding (due to a lack of platelets).

Government Support
The studies described in the presentation were funded by grants AI107340, AI088928, AI084288, and AI084301 awarded by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health to Bolder BioTechnology.

About Bolder BioTechnology
Bolder BioTechnology, Inc. is a private company that uses advanced protein engineering and bioconjugation technologies to create easier to use, safer and more cost-effective human protein pharmaceuticals. For additional information about Bolder BioTechnology, Inc., please visit www.bolderbio.com.